These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6105677)

  • 41. Catecholaminergic control of alpha-melanocyte-stimulating hormone (alpha MSH) release by frog neurointermediate lobe in vitro: evidence for direct stimulation of alpha MSH release by thyrotropin-releasing hormone.
    Tonon MC; Leroux P; Stoeckel ME; Jegou S; Pelletier G; Vaudry H
    Endocrinology; 1983 Jan; 112(1):133-41. PubMed ID: 6401174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of beta-/Tyr9/melanotropin-/9-18/ on apomorphine-induced stereotyped cage-climbing and on striatal dopamine release in mice. Comparative studies with amphetamine.
    Vécsei L; Telegdy G; Schally AV; Coy DH
    Neuropeptides; 1982 Dec; 3(2):91-6. PubMed ID: 6891751
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Menalocyte stimulating hormone and MSH/ACTH4-10 reduce tonic immobility in the lizard.
    Stratton LO; Kastin AJ
    Physiol Behav; 1976 Jun; 16(6):771-4. PubMed ID: 10593
    [No Abstract]   [Full Text] [Related]  

  • 44. Alpha-MSH and MIF-2 effects on serotonin levels and accumulation in various rat brain areas.
    Spirtes MA; Kostrzewa RM; Kastin AJ
    Pharmacol Biochem Behav; 1975; 3(6):1011-5. PubMed ID: 4814
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Attenuation of morphine tolerance and dependence by alpha-melanocyte stimulating hormone(alpha-MSH).
    Székely JI; Miglécz E; Dunai-Kovács Z; Tarnawa I; Rónai AZ; Gráf L; Bajusz S
    Life Sci; 1979 May; 24(21):1931-8. PubMed ID: 37395
    [No Abstract]   [Full Text] [Related]  

  • 46. Effects of hypothalamic lesions and drugs interfering with dopaminergic transmission on pituitary MSH content of rats.
    Tilders FJ; Smelik PG
    Neuroendocrinology; 1978; 25(5):275-90. PubMed ID: 206853
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Behavioral effects of melanocyte stimulating hormone release-inhibiting factor-1 (MIF-1).
    von Almen TK; Olson GA; Olson RD
    Neurosci Biobehav Rev; 1983; 7(2):257-62. PubMed ID: 6136015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Neuroleptic treatment for a substantial proportion of adult life: behavioural sequelae of 9 months haloperidol administration.
    Waddington JL; Gamble SJ
    Eur J Pharmacol; 1980 Oct; 67(4):363-9. PubMed ID: 7192633
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Modulation of dopamine receptor sensitivity by estrogen.
    Gordon JH; Borison RL; Diamond BI
    Biol Psychiatry; 1980 Jun; 15(3):389-96. PubMed ID: 7189674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral tardive dyskinesia in the rat.
    Sundén-Kuronen B; Pohto P; Alanen E
    Acta Odontol Scand; 1983 Dec; 41(6):343-8. PubMed ID: 6581673
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Similar effect of estradiol and haloperidol on experimental tardive dyskinesia in monkeys.
    Bédard PJ; Boucher R; Daigle M; Di Paolo T
    Psychoneuroendocrinology; 1984; 9(4):375-9. PubMed ID: 6514933
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of lithium on an animal model of tardive dyskinesia.
    Klawans HL; Weiner WJ; Nausieda PA
    Prog Neuropsychopharmacol; 1977; 1(1-2):53-60. PubMed ID: 569341
    [No Abstract]   [Full Text] [Related]  

  • 53. Radio-frequency analysis of the effect of haloperidol and cyclo (leucyl-glycyl) on apomorphine-induced stereotypy.
    Fields JZ; Gonzalez LP; Meyerson LR; Lieber P; Lee JM; Steece KA; DeLeon-Jones FA; Ritzmann RF
    Pharmacol Biochem Behav; 1986 Dec; 25(6):1279-84. PubMed ID: 3809231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. MIF-induced augmentation of melatonin functions: possible relevance to mechanisms of action of MIF-1 in movement disorders.
    Sandyk R
    Int J Neurosci; 1990 May; 52(1-2):59-65. PubMed ID: 1979968
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective effect of Curcumin, the active principle of turmeric (Curcuma longa) in haloperidol-induced orofacial dyskinesia and associated behavioural, biochemical and neurochemical changes in rat brain.
    Bishnoi M; Chopra K; Kulkarni SK
    Pharmacol Biochem Behav; 2008 Feb; 88(4):511-22. PubMed ID: 18022680
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Potentiation of apomorphine-induced stereotypies by naloxone and L-prolyl-L-leucyl-glycinamide.
    Quock RM; Lucas TS; Hartl TJ
    Pharmacol Biochem Behav; 1983 Jul; 19(1):49-52. PubMed ID: 6137836
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
    Gordon JH; Diamond BI
    Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neurological effects of MIF-1, MSH, and opiate peptides in clinical studies.
    Kastin AJ; Ehrensing RH; Olson RD; Coy DH
    Int J Neurol; 1980; 14(2-4):205-9. PubMed ID: 6152908
    [No Abstract]   [Full Text] [Related]  

  • 59. Tardive dyskinesia: behavioral effects of repeated intracerebroventricular haloperidol injections in rats do not confirm the kindling hypothesis.
    Andreassen OA; Jørgensen HA
    Pharmacol Biochem Behav; 1994 Oct; 49(2):309-12. PubMed ID: 7824543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Anticholinergics promote neuroleptic-induced tardive dyskinesia.
    Borison RL; Diamond BI
    Adv Biochem Psychopharmacol; 1980; 24():359-61. PubMed ID: 6105786
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.